SOUTH BEND, IN, Sep 29, 2010 — Kraig Biocraft Laboratories, (OTCBB: KBLB ) is very pleased to announce that the following release was made by the University of Notre Dame moments ago.

Notre Dame and University of Wyoming scientists genetically engineer silkworms to produce artificial spider silk

A research and development effort by the University of Notre Dame, the University of Wyoming, and Kraig Biocraft Laboratories, Inc. has succeeded in producing transgenic silkworms capable of spinning artificial spider silks.

“This research represents a significant breakthrough in the development of superior silk fibers for both medical and non-medical applications,” said Malcolm J. Fraser Jr., a Notre Dame professor of biological sciences. “The generation of silk fibers having the properties of spider silks has been one of the important goals in materials science.”

Natural spider silks have a number of unusual physical properties, including significantly higher tensile strength and elasticity than naturally spun silkworm fibers. The artificial spider silks produced in these transgenic silkworms have similar properties of strength and flexibility to native spider silk.

Silk fibers have many current and possible future biomedical applications, such as use as fine suture materials, improved wound healing bandages, or natural scaffolds for tendon and ligament repair or replacement. Spider silk-like fibers may also have applications beyond biomedical uses, such as in bulletproof vests, strong and lightweight structural fabrics, a new generation athletic clothing and improved automobile airbags.

Until this breakthrough, only very small quantities of artificial spider silk had ever been produced in laboratories, but there was no commercially viable way to produce and spin these artificial silk proteins. Kraig Biocraft believed these limitations could be overcome by using recombinant DNA to develop a bio-technological approach for the production of silk fibers with a much broader range of physical properties or with pre-determined properties, optimized for specific biomedical or other applications.

The firm entered into a research agreement with Fraser, who discovered and patented a powerful and unique genetic engineering tool called “piggyBac.” PiggyBac is a piece of DNA — known as a transposon that can insert itself into the genetic machinery of a cell.

“Several years ago, we discovered that the piggyBac transposon could be useful for genetic engineering of the silkworm, and the possibilities for using this commercial protein production platform began to become apparent.”

Fraser, with the assistance of University of Wyoming researcher Randy Lewis, a biochemist who is one of the world’s foremost authorities on spider silk, and Don Jarvis, a noted molecular geneticist who specializes in insect protein production, genetically engineered silkworms in which they incorporated specific DNAs taken from spiders. When these transgenic silkworms spin their cocoons, the silk produced is not ordinary silkworm silk, but, rather, a combination of silkworm silk and spider silk. The genetically engineered silk protein produced by the transgenic silkworms has markedly improved elasticity and strength approaching that of native spider silk.

“We’ve also made strides in improving the process of genetic engineering of these animals so that the development of additional transgenics is facilitated,” Fraser said. “This will allow us to more rapidly assess the effectiveness of our gene manipulations in continued development of specialized silk fibers.”

Since silkworms are already a commercially viable silk production platform, these genetically engineered silkworms effectively solve the problem of large scale production of engineered protein fibers in an economically practical way.

“Using this entirely unique approach, we have confirmed that transgenic silkworms can be a potentially viable commercial platform for production of genetically engineered silk proteins having customizable properties of strength and elasticity,” Fraser said. “We may even be able to genetically engineer fibers that exceed the remarkable properties of native spider silk.”

The genetic engineering breakthrough was announced today (Sept. 29) by Dr. Fraser, Dr. Lewis and Kraig Biocraft CEO Kim Thompson at a press conference on the Notre Dame campus.

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: https://kraiglabs.com

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

CONTACT:

Ben Hansel (720) 288-8495

Email Contact:

benhansel@yahoo.com

LANSING, Mich., September 24, 2010 — Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) is very pleased to announce that the University of Notre Dame and Kraig Biocraft Laboratories will hold a joint press conference Wednesday, September 29, 2010 on the Notre Dame campus to describe a new research breakthrough and its possible biomedical and commercial applications.

The press conference will take place in the University of Notre Dame’s Jordan Hall of Science at 11:00 A.M. Due to space limitations, media only please. For invitations and further details the media are invited to contact Ben Hansel (720) 288-8495.

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: https://kraiglabs.com

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

CONTACT: Ben Hansel (720) 288-8495 benhansel@yahoo.com

LANSING, Mich., September 20, 2010 — Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) announced that the company anticipates releasing definitive details about its upcoming press conference, including date, time and place, later this week.

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: https://kraiglabs.com

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

CONTACT: CONTACT: Ben Hansel (720) 288-8495

LANSING, MI — (Marketwire) — 09/13/10 — Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), a biotechnology company focused on the development of spider silk based materials, today updated its press release from September 7 by confirming that scientists working in collaboration with the Company have successfully genetically engineered silkworm moths with select spider genes.

The spider-moths were developed as a part of the Company’s product development program that is aimed at utilizing transgenic silkworms to produce spider silk. The Company believes that spider silk has numerous potential commercial and industrial applications in the hundred billion dollar technical textiles market.

The silkworms were successfully genetically engineered with the Company’s targeted spider silk DNA sequences.

“In response to the feedback from our September 7th press release regarding genetically engineered silkworm, we are happy to readdress our press release here in layman’s terms. While transgenic silkworm is the proper scientific term, laymen may better understand what we have accomplished as genetically engineered spider-moths,” said CEO Kim K. Thompson. “The genetically engineered silkworms are true moths which have been transformed with only one carefully targeted spider silk gene sequence. That gene sequence relates specifically to silk production.”

Thompson added, “We believe that the spider DNA has fully integrated into the silkworm chromosome. This genetic engineering success clears a major hurdle in our path; it puts us well ahead of our product development schedule and will allow us to further accelerate product development.”

The Company plans to hold a press conference to discuss other significant laboratory developments. That conference is expected to take place later this month.

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: www.KraigLabs.com

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT:
Kraig Biocraft Laboratories, Inc.
Kim K. Thompson
CEO
(517) 336-0807

LANSING, MI — (Marketwire) — 09/07/10 — Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), a biotechnology company focused on the development of commercially significant high performance polymers including spider silk, today confirmed that scientists working in collaboration with the Company have successfully created transgenic silkworms. The silkworms were successfully genetically engineered with targeted spider silk DNA sequences.

“We are very excited to be able to announce our genetic engineering success,” said CEO Kim K. Thompson. “The creation of these transgenics was greeted with much celebration among the scientists and in the corporate office. In my view our accomplishment establishes that we have been on the right track all along. This achievement is a landmark event for the Company. It clears a major hurdle in our path and puts us well ahead of our development schedule.”

In addition to the news released today, the Company plans to hold a press conference to discuss other significant laboratory developments. That conference is expected to take place later this month.

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: www.KraigLabs.com

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT:
Kraig Biocraft Laboratories, Inc.
Kim K. Thompson
CEO
(517) 336-0807

LANSING, Mich., August 24, 2010 –Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), a biotechnology company focused on the development of commercially significant high performance polymers including spider silk, is sending out an advance press advisory today describing the Company’s plan to hold a press conference for the purpose of announcing laboratory developments. The press conference is tentatively scheduled for mid to late September.

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: www.KraigLabs.com

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com

Kraig Biocraft Laboratories, Inc.
120 North Washington Square, Suite 805
Lansing , Michigan 48933

August 24, 2010

Dear Shareholder,

Kraig Biocraft Laboratories has made great strides in the last several months, and I believe that we, as a company, are gaining significant momentum both in the laboratory and in terms of corporate developments.

On the corporate side, one of the most difficult challenges and hurdles faced by the Company was navigating the credit crunch and meltdown of the US and European financial sectors in 2008 and its aftermath. Many advanced biotechnology companies collapsed and permanently closed their doors as their sources of finance dried up. I was personally saddened to see the biotechnology industry decimated by the financial meltdown that it had no part in creating.

I was determined that Kraig would not suffer the fate of others in our industry just at the time when we believed that we were on the verge of remarkable progress. We took immediate action and implemented a strategy which combined streamlining our already lean operations, a ten for one forward stock split and an S1 Securities registration. It has taken more than a year for that plan to play out, but in late June we were able to announce that our S1 had been declared effective.

What enabled Kraig to survive the financial meltdown when larger biotechnology companies all around us were collapsing was a combination of our innovative business strategy and our perseverance based on the knowledge of the importance and viability of our work. As a vital and essential part of our corporate community we want to thank you our shareholders for your vision and fortitude. We have now ridden together through some of the toughest times in our nation’s financial history.

Even before our S1 registration was declared effective, we had the confidence in our business model to negotiate a new collaborative research and development agreement with the University of Notre Dame. This agreement replaces our prior agreement with the university and places Kraig on sound footing for further scientific developments in 2010 and 2011. A word of acknowledgement for the work and vision of the university researchers and administrators is in order here.

Of course, while all this has been going on, and while the stock markets have fallen and partially risen, scientists, researchers and genetic engineers have continued to work for the creation and material development of the Company’s vision for high performance polymers including most notably recombinant spider silk.

This morning the Company issued a press conference advisory. Kraig plans to hold a press conference for the purpose of announcing laboratory developments. I have tentatively scheduled the conference for mid to late September. This is a very exciting time for the Company.

While we as a company are greatly looking forward to September, I do believe that our future over the next twelve months will be even brighter. We appear to be gaining momentum in the laboratory, and we believe that in the coming months we will be able to build on the foundations that have been laid by our researchers over the last year.

Thank you again for sticking with us when promising technology companies all around us were collapsing. I do believe that the coming months of 2010 and most especially the coming year of 2011 will be the best and brightest for Kraig Biocraft Laboratories.

Kim Thompson, CEO

Forward-looking statements:

This document includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

LANSING, MI, Aug 05, 2010 (MARKETWIRE via COMTEX) — KraigBiocraft Laboratories, Inc. (OTCBB: KBLB ), a biotechnology company focused on the development of commercially significant high performance polymers including spider silk, today confirmed that earlier this year the Company entered into a new collaborative research and development agreement with the University of Notre Dame relating to the development of new polymers.

“The rate of progress and scientific development achieved over the last twelve months has exceeded our expectations. I believe that we are now ahead of our scheduled timeline for R&D and product development,” said Kim Thompson, Kraig CEO. “The new collaborative research agreement was designed to help us maintain that momentum. We are also hopeful that our recently completed S1 registration will enable the Company to further accelerate our development of new materials.”

For more information on KraigBiocraft Laboratories please visit the Company’s web site: www.KraigLabs.com

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT:

Kraig Biocraft Laboratories, Inc.

Kim K. Thompson CEO

LANSING, Mich., Jun 22, 2010 (BUSINESS WIRE) — Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB ), a biotechnology company focused on the development of commercially significant high performance polymers and technical fiber including spider silk, is very pleased to announce that its S1 registration statement has been declared effective. The Company filed the S1 registration statement in October of 2009 and has been working diligently over the last nine months to obtain this clearance.

“After working on this for nearly nine months, we are very happy to announce that the SEC has informed the Company that its S1 registration is now effective,” said CEO Kim K. Thompson. “The S1 registration lays the foundation for our financing program over the next twenty four months. When we originally filed the S1 our legal advisors told us that we could expect a delay of at least forty five days. Those forty five days ultimately turned into almost nine months. While we have been pursuing this clearance our legal advisors informed us that the Company should limit its public communication to avoid the perception of any promotion. We want to thank all of our shareholders for their patience during this arduous process and we look forward to what we now believe will be a very successful year for Kraig Biocraft Laboratories.”

Kraig is working to develop and commercialize high performance polymers using spider silk gene sequences. The company plans to tap into the $92 billion market for high performance and technical fibers. In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of scientific research and development within the university.

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: www.KraigLabs.com

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. is applying its proprietary genetic engineering technology to find solutions in the areas of material science. Kraig has obtained the exclusive right, in their field of research, for the spider silk gene sequences which are at the core of their technology. These genetic sequences were first studied and subsequently patented by Dr. Lewis of the University of Wyoming. In early 2006, the company obtained certain exclusive rights from the University to utilize the sequences in our field of use. Spider Silk is among the strongest fibers produced in nature with potentially broad applications for consumers and industry in the multi-billion dollar marketplace for high performance polymers.

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

SOURCE: Kraig Biocraft Laboratories, Inc.

CONTACT: Kraig Biocraft Laboratories, Inc. Kim K. Thompson, CEO

LANSING, Mich., May 29, 2009 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) is pleased to announce that it has successfully issued its stock dividend. “The issuance of the dividend has been in the planning for some time and has been an important part of the Company’s plan for returning value to our shareholders. Just as important, we believe that the issuance has laid the groundwork for the Company’s long term future,” said CEO Kim K Thompson. “The input we have received from our shareholders throughout this process has been and continues to be overwhelmingly positive. We are also very excited about the progress in the laboratory and are very hopeful that the scientific team can maintain their tremendous forward momentum through the summer and fall and into 2010.”

Kraig is working to develop and commercialize high performance polymers using spider silk gene sequences. The company plans to tap into the $92 billion market for high performance and technical fibers. In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of scientific research and development within the university.

For more information on Kraig Biocraft Laboratories, and to hear an audio interview with Kraig’s CEO, please visit the Company’s web site: www.KraigLabs.com

The Kraig Biocraft Laboratories, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4817

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT:

Kraig Biocraft Laboratories, Inc.
Kim K. Thompson, CEO

(517) 336-0807